BioSig Technologies Inc. Enters Merger Talks with Streamex Exchange Corp.

BioSig Technologies, Inc., a medical technology company specializing in signal processing solutions for cardiac catheter ablations, has entered into a Letter of Intent (LOI) to merge with Streamex Exchange Corp. This development is a significant milestone for BioSig, a company listed on the Nasdaq stock exchange and operating within the Health Care Equipment & Supplies sector.

BioSig Technologies is known for its innovative technology that enhances catheter ablation procedures for complex arrhythmias, such as ventricular tachycardia. By improving these procedures, the company contributes to advancements in health care equipment and supplies. The merger talks with Streamex Exchange Corp. could potentially impact BioSig’s future operations and valuation.

As of the latest available data, BioSig’s stock price closed at $1.45 USD. Over the past year, the company’s stock has experienced fluctuations, with a 52-week high of $2.57 USD on May 28, 2024, and a 52-week low of $0.201 USD on June 11, 2024. The company’s market capitalization stands at approximately $61,843,822 USD.

The merger discussions between BioSig Technologies and Streamex Exchange Corp. are closely watched by investors and industry analysts, given the potential implications for both companies’ strategic directions and market positions. Further details on the merger’s terms and conditions are expected to be disclosed as negotiations progress.

For more information, BioSig Technologies can be accessed through its website at www.biosig.com .